183 related articles for article (PubMed ID: 28426702)
1. Natalizumab stabilizes physical, cognitive, MRI, and OCT markers of disease activity: A prospective, non-randomized pilot study.
Talmage GD; Coppes OJM; Javed A; Bernard J
PLoS One; 2017; 12(4):e0173299. PubMed ID: 28426702
[TBL] [Abstract][Full Text] [Related]
2. A longitudinal uncontrolled study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis.
Khalid F; Tauhid S; Chua AS; Healy BC; Stankiewicz JM; Weiner HL; Bakshi R
Int J Neurosci; 2017 May; 127(5):396-403. PubMed ID: 27143245
[TBL] [Abstract][Full Text] [Related]
3. Practice effect in Symbol Digit Modalities Test in multiple sclerosis patients treated with natalizumab.
Roar M; Illes Z; Sejbaek T
Mult Scler Relat Disord; 2016 Nov; 10():116-122. PubMed ID: 27919477
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid levels of neurofilament and tau correlate with brain atrophy in natalizumab-treated multiple sclerosis.
Mellergård J; Tisell A; Blystad I; Grönqvist A; Blennow K; Olsson B; Dahle C; Vrethem M; Lundberg P; Ernerudh J
Eur J Neurol; 2017 Jan; 24(1):112-121. PubMed ID: 27699930
[
